Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

References

• Irving P, de Lusignan S, Tang D, et al. Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study. BMJ Open Gastroenterol. 2021;8(1):e000573. doi:10.1136/bmjgast-2020-000573
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11(4):243–255. doi:10.1038/nrgastro.2013.253
   PubMed Web of Science ®Google Scholar
• Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol. 2014;7:359–367. doi:10.2147/CEG.S45297
   PubMedGoogle Scholar
• Annese V, Daperno M, Rutter M, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohn's Colitis. 2013;7(12):982–1018. doi:10.1016/j.crohns.2013.09.016
   Google Scholar
• Chen Y, Wang L, Feng S, et al. The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract. 2020;2020:3467419. doi:10.1155/2020/3467419
   PubMed Web of Science ®Google Scholar
• Johne B, Fagerhol M, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50(3):113–123. doi:10.1136/mp.50.3.113
   PubMedGoogle Scholar
• Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14(1):32–39. doi:10.1002/ibd.20275
   PubMed Web of Science ®Google Scholar
• Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7(4):460–465. doi:10.3748/wjg.v7.i4.460
   PubMed Web of Science ®Google Scholar
• Kostas A, Siakavellas S, Kosmidis C, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol. 2017;23(41):7387–7396. doi:10.3748/wjg.v23.i41.7387
   PubMed Web of Science ®Google Scholar
• Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22(3):340–345. doi:10.1097/MEG.0b013e32832bab49
   PubMed Web of Science ®Google Scholar
• Walsh A, Kormilitzin A, Hinds C, et al. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. J Crohn's Colitis. 2019;13(4):424–430. doi:10.1093/ecco-jcc/jjy184
   Google Scholar
• Jones S, Jenkins B. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773–789. doi:10.1038/s41577-018-0066-7
   PubMed Web of Science ®Google Scholar
• West N, Hegazy A, Owens B, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579–589. doi:10.1038/nm.4307
   PubMed Web of Science ®Google Scholar
• Verstockt S, Verstockt B, Machiels K, et al. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(10):1564–1575. doi:10.1093/ibd/izab032
   PubMed Web of Science ®Google Scholar
• Verstockt B, Verstockt S, Dehairs J, et al. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. EBioMedicine. 2019;40:733–742. doi:10.1016/j.ebiom.2019.01.027
   PubMed Web of Science ®Google Scholar
• Nishioka K, Ogino H, Chinen T, et al. Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease. J Gastroenterol. 2021;56(11):976–987. doi:10.1007/s00535-021-01819-7
   PubMed Web of Science ®Google Scholar
• Minar P, Lehn C, Tsai Y, et al. Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. Crohn’s & Colitis. 2019;1(3):otz026. doi:10.1093/crocol/otz026
   PubMedGoogle Scholar
• Mateos B, Sáez-González E, Moret I, et al. Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn’s Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. Dig Dis. 2021;39(1):1–9. doi:10.1159/000508069
   PubMed Web of Science ®Google Scholar
• Bertani L, Fornai M, Fornili M, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284–291. doi:10.1111/apt.15870
   PubMed Web of Science ®Google Scholar
• Kalla R, Adams A, Bergemalm D, et al. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. J Crohn's Colitis. 2021;15(5):699–708. doi:10.1093/ecco-jcc/jjaa230
   Google Scholar
• Gong Y, Yan X, Sun X, et al. Oncostatin M Is a Prognostic Biomarker and Inflammatory Mediator for Sepsis. J Infect Dis. 2020;221(12):1989–1998. doi:10.1093/infdis/jiaa009
   PubMed Web of Science ®Google Scholar
• Tsui F, Lin A, Sari I, et al. Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis. Arthritis Res Ther. 2021;23(1):141. doi:10.1186/s13075-021-02521-y
   PubMed Web of Science ®Google Scholar
• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn's Colitis. 2019;13(2):144–164. doi:10.1093/ecco-jcc/jjy113
   Google Scholar
• Schroeder K, Tremaine W, Ilstrup D. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629. doi:10.1056/NEJM198712243172603
   PubMed Web of Science ®Google Scholar
• Harvey R, Bradshaw J. A simple index of Crohn’s-disease activity. Lancet. 1980;1(8167):514. doi:10.1016/S0140-6736(80)92767-1
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512. doi:10.1016/S0016-5107(04)01878-4
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn W, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi:10.1056/NEJMoa050516
   PubMed Web of Science ®Google Scholar
• Mak L, Tong T, Cheung K, et al. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020;11(3):e00138. doi:10.14309/ctg.0000000000000138
   PubMedGoogle Scholar
• Takaki Y, Mizuochi T, Eda K, et al. Laboratory values in Japanese children with newly diagnosed inflammatory bowel disease. Pediatr Int. 2019;61(7):720–725. doi:10.1111/ped.13892
   PubMed Web of Science ®Google Scholar
• Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011;106(11):2029–2040. doi:10.1038/ajg.2011.231
   PubMed Web of Science ®Google Scholar
• Chang M, Chou J, Chen S, et al. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. Mol Med Report. 2014;10(1):522–526. doi:10.3892/mmr.2014.2180
   PubMed Web of Science ®Google Scholar
• Bennike T, Birkelund S, Stensballe A, et al. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol. 2014;20(12):3231–3244. doi:10.3748/wjg.v20.i12.3231
   PubMed Web of Science ®Google Scholar
• Shen J, Qiao Y, Ran Z, et al. Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse. Int J Clin Exp Pathol. 2013;6(5):917–925.
   PubMed Web of Science ®Google Scholar
• Shimoyama T, Yamamoto T, Umegae S, et al. Faecal biomarkers for screening small bowel inflammation in patients with Crohn’s disease: a prospective study. Therap Adv Gastroenterol. 2017;10(8):577–587. doi:10.1177/1756283X17717683
   PubMed Web of Science ®Google Scholar
• Canani R, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40(7):547–553. doi:10.1016/j.dld.2008.01.017
   PubMedGoogle Scholar
• Ye L, Cheng W, Chen B, et al. Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn’s Disease: a Retrospective Cohort Study. Sci Rep. 2017;7(1):1970. doi:10.1038/s41598-017-02111-6
   PubMed Web of Science ®Google Scholar
• Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al. High C-reactive protein in Crohn’s disease patients predicts nonresponse to infliximab treatment. J Crohn's Colitis. 2014;8(2):129–136. doi:10.1016/j.crohns.2013.07.005
   Google Scholar
• Oh K, Oh EH, Baek S, et al. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn’s disease. PLoS One. 2017;12(6):e0179266. doi:10.1371/journal.pone.0179266
   PubMed Web of Science ®Google Scholar
• Mańkowska-Wierzbicka D, Karczewski J, Poniedziałek B, et al. C-reactive protein as a diagnostic and prognostic factor in inflammatory bowel diseases. Postepy Hig Med Dosw. 2016;70:1124–1130. doi:10.5604/17322693.1223798
   Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518–1523. doi:10.1136/gut.2007.146357
   PubMed Web of Science ®Google Scholar
• Buisson A, Mak W, Andersen M, et al. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohn's Colitis. 2019;13(8):1012–1024. doi:10.1093/ecco-jcc/jjz023
   Google Scholar
• Kwapisz L, Gregor J, Chande N, et al. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scand J Gastroenterol. 2017;52(8):846–850. doi:10.1080/00365521.2017.1315740
   PubMed Web of Science ®Google Scholar
• Rottenstreich A, Mishael T, Granovsky S, et al. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. Eur J Intern Med. 2020;77:105–110. doi:10.1016/j.ejim.2020.03.015
   PubMedGoogle Scholar
• Sorrentino D, Terrosu G, Paviotti A, et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn’s disease: partial benefit by infliximab–a pilot study. Dig Dis Sci. 2012;57(5):1341–1348. doi:10.1007/s10620-011-2025-z
   PubMed Web of Science ®Google Scholar
• Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, et al. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. J Clin Gastroenterol. 2016;50(2):147–151. doi:10.1097/MCG.0000000000000312
   PubMed Web of Science ®Google Scholar
• Stevens T, Gecse K, Turner J, et al. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020;19(11):2333–2342. doi:10.1016/j.cgh.2020.08.019
   PubMed Web of Science ®Google Scholar
• Ladipo J, He Z, Chikwava K, et al. Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort. J Pediatr Gastroenterol Nutr. 2021;73(3):352–357. doi:10.1097/MPG.0000000000003201
   PubMed Web of Science ®Google Scholar
• Dragoni G, Innocenti T, Galli A. Biomarkers of Inflammation in Inflammatory Bowel Disease: how Long before Abandoning Single-Marker Approaches? Dig Dis. 2021;39(3):190–203. doi:10.1159/000511641
   PubMed Web of Science ®Google Scholar
• Ishida N, Miyazu T, Takano R, et al. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. BMC Gastroenterol. 2020;20(1):114. doi:10.1186/s12876-020-01256-5
   PubMed Web of Science ®Google Scholar
• Con D, Parthasarathy N, Bishara M, et al. Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn’s Disease. J Crohn's Colitis. 2021;15(4):583–593. doi:10.1093/ecco-jcc/jjaa194
   Google Scholar